Video and Synthetic MRI Pre-training of 3D Vision Architectures for Neuroimage Analysis

Transfer learning represents a recent paradigm shift in the way we build artificial intelligence (AI) systems. In contrast to training task-specific models, transfer learning involves pre-training deep learning models on a large corpus of data and minimally fine-tuning them for adaptation to specific tasks. Even so, for 3D medical imaging tasks, we do not know if it is best to pre-train models on natural images, medical images, or even synthetically generated MRI scans or video data. To evaluate these alternatives, here we benchmarked vision transformers (ViTs) and convolutional neural networks (CNNs), initialized with varied upstream pre-training approaches. These methods were then adapted to three unique downstream neuroimaging tasks with a range of difficulty: Alzheimer's disease (AD) and Parkinson's disease (PD) classification, "brain age" prediction. Experimental tests led to the following key observations: 1. Pre-training improved performance across all tasks including a boost of 7.4% for AD classification and 4.6% for PD classification for the ViT and 19.1% for PD classification and reduction in brain age prediction error by 1.26 years for CNNs, 2. Pre-training on large-scale video or synthetic MRI data boosted performance of ViTs, 3. CNNs were robust in limited-data settings, and in-domain pretraining enhanced their performances, 4. Pre-training improved generalization to out-of-distribution datasets and sites. Overall, we benchmarked different vision architectures, revealing the value of pre-training them with emerging datasets for model initialization. The resulting pre-trained models can be adapted to a range of downstream neuroimaging tasks, even when training data for the target task is limited

Semi-automated PIRADS scoring via mpMRI analysis

Purpose: Prostate cancer (PCa) is the most common solid organ cancer and second leading cause of death in men. Multiparametric magnetic resonance imaging (mpMRI) enables detection of the most aggressive, clinically significant PCa (csPCa) tumors that require further treatment. A suspicious region of interest (ROI) detected on mpMRI is now assigned a Prostate Imaging-Reporting and Data System (PIRADS) score to standardize interpretation of mpMRI for PCa detection. However, there is significant inter-reader variability among radiologists in PIRADS score assignment and a minimal input semi-automated artificial intelligence (AI) system is proposed to harmonize PIRADS scores with mpMRI data. Approach: The proposed deep learning model (the seed point model) uses a simulated single-click seed point as input to annotate the lesion on mpMRI. This approach is in contrast to typical medical AI-based approaches that require annotation of the complete lesion. The mpMRI data from 617 patients used in this study were prospectively collected at a major tertiary U.S. medical center. The model was trained and validated to classify whether an mpMRI image had a lesion with a PIRADS score greater than or equal to PIRADS 4. Results: The model yielded an average receiver-operator characteristic (ROC) area under the curve (ROC-AUC) of 0.704 over a 10-fold cross-validation, which is significantly higher than the previously published benchmark. Conclusions: The proposed model could aid in PIRADS scoring of mpMRI, providing second reads to promote quality as well as offering expertise in environments that lack a radiologist with training in prostate mpMRI interpretation. The model could help identify tumors with a higher PIRADS for better clinical management and treatment of PCa patients at an early stage

Harnessing clinical annotations to improve deep learning performance in prostate segmentation

PurposeDeveloping large-scale datasets with research-quality annotations is challenging due to the high cost of refining clinically generated markup into high precision annotations. We evaluated the direct use of a large dataset with only clinically generated annotations in development of high-performance segmentation models for small research-quality challenge datasets.Materials and methodsWe used a large retrospective dataset from our institution comprised of 1,620 clinically generated segmentations, and two challenge datasets (PROMISE12: 50 patients, ProstateX-2: 99 patients). We trained a 3D U-Net convolutional neural network (CNN) segmentation model using our entire dataset, and used that model as a template to train models on the challenge datasets. We also trained versions of the template model using ablated proportions of our dataset, and evaluated the relative benefit of those templates for the final models. Finally, we trained a version of the template model using an out-of-domain brain cancer dataset, and evaluated the relevant benefit of that template for the final models. We used five-fold cross-validation (CV) for all training and evaluation across our entire dataset.ResultsOur model achieves state-of-the-art performance on our large dataset (mean overall Dice 0.916, average Hausdorff distance 0.135 across CV folds). Using this model as a pre-trained template for refining on two external datasets significantly enhanced performance (30% and 49% enhancement in Dice scores respectively). Mean overall Dice and mean average Hausdorff distance were 0.912 and 0.15 for the ProstateX-2 dataset, and 0.852 and 0.581 for the PROMISE12 dataset. Using even small quantities of data to train the template enhanced performance, with significant improvements using 5% or more of the data.ConclusionWe trained a state-of-the-art model using unrefined clinical prostate annotations and found that its use as a template model significantly improved performance in other prostate segmentation tasks, even when trained with only 5% of the original dataset